Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a roadmap for how to move promising preclinical findings into the clinic.
The book discusses topics such as immunotherapy and molecularly targeted therapies in head and neck cancer, PI3k/mTOR pathway, autophagy inhibition to sensitize HNC to radiation and chemotherapy, TAM and Eph/Ephrin family proteins and metabolic reprogramming to modulate therapeutic sensitivity. Additionally, it details approaches to improve the response to immunotherapy, and Chk1/2 inhibition in radiation and cetuximab resistance.
This book is a valuable source to head and neck cancer researchers and advanced students, and to those studying specific approaches in other model systems and disease sites.
- Provides key scientific background for clinicians when developing novel clinical trials and important examples for basic scientists of the types of work required to move a concept from the lab to the clinic
- Presents consistent pathway diagrams in each chapter, thus making it easier to understand complicated pathways
- Includes chapter summaries of the critical next steps needed to move studies from their current state into practice changing clinical data
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
1. Overview of head and neck cancer management 2. The role of immunotherapy and molecularly targeted therapies in head and neck cancer 3. Targeting the PI3K/mTOR pathway 4. Autophagy inhibition to sensitize HNC to radiation and chemotherapy 5. Overcoming head and neck cancer stem cells 6. TAM Family proteins and therapy resistance 7. Eph/Ephrin family proteins and theapy resistance 8. Metabolic reprogramming to modulate therapeutic sensitivity 9. FGFR and cMET 10. Targeting GPCRs in HNC 11. Improving the response to immunotherapy 12. Chk1/2 inhibition in radiation and cetuximab resistance